CogState releases details of UBC agreement

By Dylan Bushell-Embling
Tuesday, 29 July, 2008

Melbourne's CogState [ASX: CGS] has released the terms of its planned partnership with US pharmaceutical services company United BioSource Corporation [UBC], announced last week.

Under the arrangement, CogState and UBC will join forces to provide a comprehensive cognitive testing solution for use in clinical trials.

CogState markets six computerised diagnostic products to test cognitive function. It also has a therapeutic division with two compounds in early develop for Alzheimer's and Parkinson's diseases.

Under the agreement, UBC will buy a 15 per cent share in CogState, at a cost of around $800,000. UBC will also underwrite CogState's share rights issue.

Both companies will remain separate entities. In a statement to the stock exchange, CogState stressed that the arrangement will not necessitate any management changes or job losses.

Related News

Placebos appear to reduce PMS symptoms

Women affected by premenstrual syndrome (PMS) appear to experience less intense and debilitating...

Medicinal cannabis linked to long-term health benefits

As scientists find a way to improve the effectiveness of CBD, a separate study shows that...

Sleep apnoea patients who use CPAP live longer: study

CPAP therapy has been found to significantly reduce the risk of death for people with obstructive...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd